Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV.
da Silva IP, et al. Among authors: warner ab.
Lancet Oncol. 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8.
Lancet Oncol. 2021.
PMID: 34339647
No abstract available.